Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-10-26

Clinical Trial Update: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) [Phase 3]

View source ↗

Summary

Phase 3 study of tocilizumab (RoActemra/Actemra) in active systemic juvenile idiopathic arthritis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Juvenile Idiopathic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2011-10-26